For research use only. Not for therapeutic Use.
A 71915 is a highly potent and competitive natriuretic peptide receptor A (ANP, NPRA) antagonist (pKi= 9.18). A 71915 displaces [125I]ANP dose dependently, with a Ki of 0.65 nM. A71915( pA2= 9.48) against rat ANP-induced cGMP production in NB-OK-1 cells[1].
A 71915 combines to Neuroblastoma NB-OK-1 cells, is used in the Cyclic GMP assay.
A 71915 shifts the ANP dose-response curve of cyclic GMP production to the right[1].
A 71915 (5 μl; i.m.; 25-30 g male CD-1 mice) affects BNP (1 nmol)- and GRP (0.1 nmol)-induced scratching[2].
A 71915 (30 μg/ kg/ day) inhibits NS-398 on blood pressure decreased[3].
| Catalog Number | I021133 |
| CAS Number | 132956-87-7 |
| Molecular Formula | C69H116N26O15S2 |
| Purity | ≥95% |
| Reference | [1]. Delporte C, et al. Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line. Eur J Pharmacol. 1992;224(2-3):183-188. [2]. Kiguchi N, et al. Spinal Functions of B-Type Natriuretic Peptide, Gastrin-Releasing Peptide, and Their Cognate Receptors for Regulating Itch in Mice. [3]. Park BM, et al. Attenuation of renovascular hypertension by cyclooxygenase-2 inhibitor partly through ANP release. Peptides. 2015;69:1-8. |
